Estrogen mediated regulation of TGFβ pathway signaling in cardiac hypertrophy (795.4)

Payton Malone,Tyler Burton

DOI: https://doi.org/10.1096/fasebj.28.1_supplement.795.4

2014-04-01

The FASEB Journal

Abstract:It is well documented that pre‐menopausal women are protected from heart disease, in part through the effects of estrogen. It has been established that estrogen treatment prevents cardiomyocyte hypertrophy and that estrogen attenuates the prohypertrophy TGFBeta (TGFb) signaling family. However, it has yet to be established whether estrogen is in part mediating its cardioprotective effects via the silencing of TGFb signaling. To address the differential control of the TGFb family member expression in female vs. male mice in the setting of cardiac hypertrophy, we performed transaortic constriction (TAC) to induce hypertrophy. We then analyzed gene and miRNA expression for TGFb family members and potential targeting miRNAs, several of which are known to be induced by estrogen. Next Generation Sequencing was performed to establish miRNA profiles in male and female following the TAC. Differential expression of TGFb targeting miRNAs was confirmed by TaqMan assays. TaqMan also revealed that many of the TGFb family members were preferentially downregulated in female TAC mice as compared to age matched male TAC mice. To define the mechanisms by which estrogen regulates TGFb expression we are performing a series of estrogen receptor activation studies in an in vitro cardiomyocyte hypertrophy model system. Preliminary results show distinct activation of TGFb family members and targeting miRNAs in the traditional nuclear receptors. The direct role for estrogen‐induced miRNAs will be further investigated using antagomirs in vitro. These data taken together will define the underlying estrogen mediated pathways related to TGFb signaling and could lead to new therapeutic targets for heart disease. Grant Funding Source : Supported by an Institutional Development Award (IDeA) under grant number R15HL108192